This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program (iCARE)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Piedmont Healthcare Identifier:
First received: August 31, 2009
Last updated: May 18, 2016
Last verified: May 2016
This study will evaluate the effectiveness of an individualized approach to diagnosing and/or treating atherosclerosis. This will be done by combining genetic information, lifestyle information, participant education, and imaging tests to track diagnoses, therapies, and treatment on two groups: 1) Standard Management Group (diagnosed and/or treated according to standard of care) and 2) Individualized Management Group (standard of care plus genetic testing and coronary artery calcium scans).


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program

Resource links provided by NLM:

Further study details as provided by Piedmont Healthcare:

Primary Outcome Measures:
  • To determine the proportion of subjects and patients who are diagnosed with subclinical and clinically significant coronary atherosclerosis with the PHI-ACE-iCARE approach, compared to the current guideline-driven approach. [ Time Frame: 6 months, 12 months, 18 months ]

Secondary Outcome Measures:
  • To determine the proportion of patients who receive appropriate revascularization procedures for clinically significant coronary atherosclerosis with the PHI-ACE-iCARE approach, compared to the current guideline-driven approach. [ Time Frame: 6 month, 12 months, 18 months ]

Enrollment: 170
Study Start Date: October 2011
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Individualized Managment Group
Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.
Standard Management Group
Participants who receive standard of care.

Detailed Description:
The purpose of this proposal is to create a large, community-based demonstration project to evaluate the value of a highly individualized approach to atherosclerosis risk reduction. In this project we set out to compare the delivery of appropriate therapies and resource utilization using current national guidelines for the management of atherosclerosis and will compare this to using a highly individualized approach for atherosclerosis risk reduction, based on the evaluation of specific features in individuals and tailoring management based on this evaluation. We plan to show that utilizing the iCARE Program, more patients will receive appropriate diagnoses and subsequent therapies in a more efficient manner.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Individuals with no known coronary artery disease and who have an intermediate or high Framingham Risk Score (10 year risk 10 percent or greater).

Inclusion Criteria:

  • No known coronary artery disease

    • no prior coronary disease by cardiac catheterization (≤39% in any major epicardial vessel)
    • no prior myocardial infarction
    • no prior ST-elevation myocardial infarction (1 mm ST-elevation in 2 contiguous leads)
    • no prior non-ST-elevation myocardial infarction (CK-MB > 2x ULN or elevated troponin that is indicative of myocardial necrosis based on local institutional cutpoints)
    • no prior coronary revascularization procedure
  • Intermediate or high Framingham Risk Score (10-year risk 10% or greater)
  • Ability and willingness to provide consent and Authorization for use of PHI

Exclusion Criteria:

  • Presence of known cardiomyopathy
  • Presence of permanent pacemaker, defibrillator, or CRT device
  • Presence of clinically significant, uncontrolled arrhythmia (chronic or paroxysmal atrial fibrillation is NOT an exclusion. Arrhythmias treated successfully with ablation are not an exclusion.
  • Presence of a known genetic abnormality of cholesterol metabolism (e.g. familial hypercholesterolemia)
  • Inability or unwillingness to adhere to follow up schedule
  • Inability or unwillingness to provide informed consent and Authorization for use of PHI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00969865

United States, Georgia
Piedmont Heart Institute
Atlanta, Georgia, United States, 30309
Sponsors and Collaborators
Piedmont Healthcare
Principal Investigator: Joseph Miller, MD Piedmont Heart Institute
  More Information

Responsible Party: Piedmont Healthcare Identifier: NCT00969865     History of Changes
Other Study ID Numbers: iCARE
Study First Received: August 31, 2009
Last Updated: May 18, 2016

Keywords provided by Piedmont Healthcare:

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on September 20, 2017